. "35\u201340 minutes"@en . . "investigational"@en . "Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca²⁺ from intracellular storage sites. This reduction in the influx of Ca²⁺ has been postulated to cause relaxation of the smooth muscle cells and vasodilation."@en . "Oral bioavailability is 50\u201370%."@en . . . . "88430-50-6"@en . . . . . "Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury."@en . . . . . . . . . . . . "Beraprost"@en . . "For the treatment of pulmonary hypertension."@en . . . . . "Humans and other mammals"@en . . . . . "# Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH: Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol. 2007 Jul 9;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17620284 # Melian EB, Goa KL: Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11790158"@en . . . . . .